FDA Moves on Peptides: What Compounding Pharmacies Need to Know FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies FDA Compliance for Peptide Therapy and BPC 157 Holt Law fda warning bpc 157 peptide products New Details 157 The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and clinics. With BPC 157, TB 500, and others under 503A review, questions around compounding, compliance, and what is